Low‐dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta‐analysis

By W. Burger, Chemnitius Jm, Kneissl Gd, Gerta Rücker. Journal of Internal Medicine, 2005

841 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/de1e1b873ed84c48d51286791a424acb59527512

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. O'Gara
2. Rick A. Nishimura
3. Jose Luis Zamorano
4. M. Mack
5. L. Fleisher
6. Stephan Windecker
7. C. Yancy

Citations in the corpus

• 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “The magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158).”
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “The magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158).”
• ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiov (2007, background): “(360) reviewed the surgical literature with regard to the”
• A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. (2006, background): “Burger et al.(13) have recently reported on a sound and comprehensive systematic review focusing on cardiovascular risks after aspirin peri-operative withdrawal vs.”
• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, background): “In most clinical situations, aspirin provides benefit that outweighs the bleeding risk and should be continued [214, 215].”